AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET
AIM Immunotech首席執行官Tom Equels將於美國東部時間6月5日星期三下午12:00進行直播視頻網絡研討會。
OCALA, Fla., June 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET.
佛羅里達州OCALA，2024年6月3日——AIM Immunotech股份有限公司。（紐約證券交易所美國：AIM）（“AIM”或“公司”）今天宣佈Thomas K. Equels，MS JD，首席執行官AIM將於2024年6月5日星期三參加虛擬投資者午餐會客戶系列活動。東部時間下午12點。
As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Equels will answer as many questions as possible in the time allowed.
作爲該活動的一部分，Equels先生將提供公司概述和業務前景。除了準備好的講話外，感興趣的各方還將有機會在活動期間實時提交問題。Equels先生將在允許的時間內回答儘可能多的問題。
A live video webcast of the presentation will be available on the Events page of the Company's website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
機器人演示的網絡直播視頻將在公司網站（aimimmuno.com）的“活動”頁面上提供。演示的網絡直播視頻將在現場演示後兩小時提供，並可訪問90天。有關AIM Immunotech股份有限公司的信息，請訪問aimimmuno.com並與公司聯繫。(aimimmuno.com)。演講的網絡直播視頻將在現場演示後兩小時提供，並可訪問90天。
About AIM ImmunoTech Inc.
AIM Immunotech股份有限公司是一家免疫藥品公司，專注於研究和開發治療多種癌症、免疫性疾病和病毒性疾病（包括COVID-19）的治療藥物。該公司的主要產品是一種名爲Ampligen（吡咯烷寡核苷酸）的首創調節免疫器官的藥物，具有廣泛的臨床試驗、覆蓋全球重要癌症、病毒性疾病和免疫系統疾病的廣譜活性。
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM Immunotech公司是一家免疫藥物公司，專注於研究和開發治療多種癌症、免疫失調和病毒性疾病（包括COVID-19）的治療藥物。該公司的主要產品是一種名爲Ampligen（Rintatolimod）的首創性調節免疫藥物，是一種dsRNA和高選擇性TLR3激動劑，廣泛應用於針對全球重要癌症、病毒性疾病和免疫系統疾病的臨床試驗中。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
有關更多信息，請訪問 aimimmuno.com並聯系該公司。X, LinkedIn和Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
投資者聯繫人：JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com。
譯文內容由第三人軟體翻譯。